Rivaroxaban reduces stent thrombosis risk, study says

04/19/2013 | MedPage Today (free registration)

Adding the anticoagulant rivaroxaban to dual antiplatelet therapy decreased the chances of death and stent thrombosis among patients being treated for acute coronary syndrome, according to a study in the Journal of the American College of Cardiology. The findings were based on an analysis of a 9,631-patient subgroup of the ATLAS ACS 2-TIMI 51 trial.

View Full Article in:

MedPage Today (free registration)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Senior Legal Counsel
Alcon
Fort Worth, TX
Senior Scientist - Cell Engineering Group
Pfizer
San Francisco, CA
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC